All In Biotech

Free tool

FAERS Monitor: Phesgo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761170 or its brand name (Phesgo, Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf). Reports on generic versions are filed under their own applications.

Reports

4,830

Serious

1,826

38% of reports

Hospitalization

625

Death reported

292

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event912
  • off label use902
  • diarrhoea432
  • injection site pain213
  • pain212
  • death164
  • fatigue163
  • injection site reaction162
  • pyrexia157
  • disease progression142
  • rash140
  • asthenia137
  • nausea114
  • malaise112
  • vomiting99

Reports by year received

View as table
YearReports
20205
202151
2022195
2023388
20242,853
2025763
2026575

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
no adverse eventSignal91222.020.818,349
injection site reactionSignal16210.38.81,348
disease progressionSignal1425.24.4484
off label useSignal9024.54.22,546
injection site painSignal2133.02.7291
diarrhoeaSignal4322.92.7559
pyrexia1572.01.776
asthenia1371.61.330
pain2121.51.336
rash1401.41.216
malaise1121.10.91
vomiting990.90.81
fatigue1630.90.81
death1640.80.76
nausea1140.60.526

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.